(0.09%) 5 522.00 points
(0.13%) 39 894 points
(0.21%) 19 791 points
(-0.06%) $81.58
(0.57%) $2.83
(-0.23%) $2 339.10
(0.19%) $29.58
(0.47%) $1 006.50
(0.04%) $0.932
(-0.03%) $10.53
(0.01%) $0.788
(-0.85%) $87.25
0.23% $ 8.77
Live Chart Being Loaded With Signals
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia...
Stats | |
---|---|
Dzisiejszy wolumen | 354 670 |
Średni wolumen | 385 359 |
Kapitalizacja rynkowa | 426.51M |
EPS | $-0.240 ( Q1 | 2024-05-15 ) |
Następna data zysków | ( $-0.0900 ) 2024-08-05 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-9.85 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.0130 (0.15%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-05-20 | Winningham Rick E | Sell | 15 997 | Ordinary Shares |
2024-05-20 | Sawaf Aziz | Sell | 8 635 | Ordinary Shares |
2024-05-20 | Miller Aine | Sell | 5 201 | Ordinary Shares |
2024-05-20 | Grimaud Brett A. | Sell | 9 268 | Ordinary Shares |
2024-05-20 | Farnum Rhonda | Sell | 9 268 | Ordinary Shares |
INSIDER POWER |
---|
78.95 |
Last 97 transactions |
Buy: 3 272 384 | Sell: 406 584 |
Wolumen Korelacja
Theravance Biopharma Inc Korelacja
10 Najbardziej negatywne korelacje |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Theravance Biopharma Inc Korelacja - Waluta/Towar
Theravance Biopharma Inc Finanse
Annual | 2023 |
Przychody: | $57.42M |
Zysk brutto: | $51.37M (89.46 %) |
EPS: | $-1.000 |
FY | 2023 |
Przychody: | $57.42M |
Zysk brutto: | $51.37M (89.46 %) |
EPS: | $-1.000 |
FY | 2022 |
Przychody: | $51.35M |
Zysk brutto: | $44.76M (87.17 %) |
EPS: | $-1.260 |
FY | 2021 |
Przychody: | $55.31M |
Zysk brutto: | $0.00 (0.00 %) |
EPS: | $-2.87 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Theravance Biopharma Inc
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also include Izencitinib, a gut-selective pan-janus kinase (JAK) inhibitor that is in Phase IIb/III clinical trials for the treatment of rheumatoid arthritis, myelofibrosis, and ulcerative colitis, as well as for a range of inflammatory intestinal diseases, including ulcerative colitis and Crohn's disease. In addition, the company's product portfolio comprise Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; Nezulcitinib, a lung-selective, nebulized JAK inhibitor, which is in Phase II clinical development for the potential treatment of hospitalized patients with acute lung injury caused by COVID-19; Inhaled ALK5i, a potential inhaled anti-fibrotic agent that is in Phase I for the treatment of idiopathic pulmonary fibrosis; and TD-5202, an investigational, orally administered, gut-selective, irreversible JAK3 inhibitor that is in Phase I clinical study for treatment of inflammatory intestinal diseases. Further, it offers TRELEGY for the treatment of COPD and asthma; Velusetrag, an oral and investigational medicine for gastrointestinal motility disorders; and Selective 5-HT4 Agonist for treatment of gastrointestinal motility disorders. It has a licensing and collaboration agreements with Pfizer Inc., Viatris Inc., Janssen Biotech, Inc., Alfasigma S.p.A, and Takeda Pharmaceutical Company Limited. Theravance Biopharma, Inc. was incorporated in 2013 and is based in George Town, the Cayman Islands.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej